Han Lanqing, Founder of Cyagen Biosciences and Director of the Artificial Intelligence Innovation Center at Tsinghua Pearl River Delta Research Institute, is a selected expert under China’s National Major Talent Program and a Provincial Distinguished Talent in Innovation and Entrepreneurship.

Dedicated to advancing the industrial translation and practical deployment of artificial intelligence technologies within the biomedical sector, he has undertaken more than 20 scientific research initiatives across national, provincial and municipal tiers, and is the proprietor of over 40 authorized invention patents. His serial research outputs have been published in internationally recognized authoritative journals, namely The Journal of Allergy and Clinical Immunology, EBioMedicine (a sister journal of The Lancet), and Gastroenterology.

The high-efficiency antibody discovery platform constructed upon HUGO-Ab humanized mouse models and proprietary AbSeek artificial intelligence technology has been officially shortlisted as a National Typical Application Case of AI plus Bio-Manufacturing by the Ministry of Industry and Information Technology of the People’s Republic of China (MIIT).